Skip to main content
OpenTrials
Completed

NCT Number: NCT06245811

Inflammation Markers in Hyperemesis Gravidarum

In this study, the relationship between the severity of hyperemesis gravidarum (HEG) disease and subclinical inflammatory factors such as Platelet Crit (PCT), Hemoglobin/red cell distribution width ratio (HRR), Neutrophil/lymphocyte ratio (NLR), was investigated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperemesis Gravidarum Female Urogenital Diseases and Pregnancy Complications Morning Sickness Pathological Conditions, Signs and Symptoms Pregnancy Complications Signs and Symptoms Signs and Symptoms, Digestive Urogenital Diseases Vomiting

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Yuzuncu Yil University, Faculty of Medicine

Van, Turkey (Türkiye)

About this study

A total of 215 pregnant women, 102 with hyperemesis gravidarum and 113 healthy pregnant women, were included in the study. HEG patients were divided into three groups according to the modified PUQE classification: mild (n=38), moderate (n=32) and severe (n=32).

In our study, we proposed using a new prognostic marker for HEG patients. We think that our study will be a source for future studies on HEG.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy pregnant women over 18 years of age
  • 5-16 weeks of gestation.

Exclusion criteria

Smoking, urinary tract infections, previously diagnosed psychological disorders, gastrointestinal disorders, multiple pregnancies, eating disorders, thyroid disorders, inflammatory disease, pregnancy with assisted fertilization technique.

Treatment and study plan

Primary outcomes

  1. The Pregnancy Unique Quantification of Emesis/Stomach scoring system

    Time frame: 2 months

    1: Weight loss of 5% or more since the beginning of pregnancy 2: Vomiting at least three times a day 3: A ketonuria value of +1 or higher on a urinalysis test

Secondary outcomes

  1. Body mass index

    Time frame: 2 months

    (BMI) (kg/m2) was obtained by dividing body weight (kg) by height (m2) squared

Sponsors and collaborators

Lead sponsor

Izzet Celegen

Other

Registry information

Official study title

Evaluation of the Relationship Between Hyperemesis Gravidarum (HEG) With Platelet Crit (PCT), Haemoglobin to Red Cell Distribution Width Ratio (HRR) and Neutrophil to Lymphocyte Ratio (NLR).

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 7, 2024
Registry last updated
Feb 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.